News headlines about Kite Pharma (NASDAQ:KITE) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kite Pharma earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.931397769722 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news stories that may have impacted Accern’s scoring:

Kite Pharma (NASDAQ KITE) opened at 179.79 on Wednesday. The firm’s market capitalization is $10.28 billion. Kite Pharma has a 52-week low of $39.82 and a 52-week high of $179.95. The company’s 50-day moving average price is $179.11 and its 200 day moving average price is $115.03.

Kite Pharma (NASDAQ:KITE) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.97) by $0.03. The firm had revenue of $10.10 million for the quarter, compared to analyst estimates of $9.59 million. Kite Pharma had a negative return on equity of 59.56% and a negative net margin of 1,117.44%. The company’s revenue for the quarter was up 110.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.91) earnings per share. Equities analysts predict that Kite Pharma will post ($8.24) earnings per share for the current fiscal year.

Several equities research analysts have recently commented on the company. Canaccord Genuity downgraded Kite Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, August 29th. Wedbush raised Kite Pharma from an “underperform” rating to a “neutral” rating in a report on Tuesday, August 29th. SunTrust Banks, Inc. downgraded Kite Pharma from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Guggenheim downgraded Kite Pharma from a “buy” rating to a “neutral” rating and set a $128.00 target price for the company. in a report on Monday, August 28th. Finally, BTIG Research downgraded Kite Pharma from a “buy” rating to a “neutral” rating in a report on Monday, August 28th. Thirteen analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $94.68.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/18/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-kite-pharma-kite-share-price.html.

In other news, CFO Paul L. Jenkinson sold 948 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $179.66, for a total value of $170,317.68. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Arie Belldegrun sold 26,347 shares of the business’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $179.66, for a total value of $4,733,502.02. Following the completion of the sale, the chairman now owns 135,507 shares in the company, valued at $24,345,187.62. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 194,785 shares of company stock worth $25,776,870. Corporate insiders own 14.00% of the company’s stock.

Kite Pharma Company Profile

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Insider Buying and Selling by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Stock Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related stocks with our FREE daily email newsletter.